Ranibizumab Overview Categories 21 Ophthalmological preparations21.7 Other ophthalmologicals Page headings Overview Primary Characterstics Indications Pharmacokinetics Contraindications Drug Interactions Side Effects Dosage High Risk Groups Warning / Precautions Storage Conditions Interference in Pathology Brands of Ranibizumab Manufacturers of Ranibizumab Primary Characterstics Indications Back to top Pharmacokinetics Back to top Contraindications Back to top Drug Interactions Back to top Side Effects Back to top Dosage Ranibizumab's dosage details are as follows: Dose Single Dose Frequency Route Instructions Adult Dosage 0.5 mg0.5 (0.5)As recommended.intravitrealonce a month (approximately 28 days). Although less effective, treatment may be reduced to one injection every three months after the first four injections if monthly injections are not feasible. Compared to continued monthly dosing, dosing every 3 months will lead to an approximate 5-letter (1-line) loss of visual acuity benefit, on average, over the following 9 months. Patients should be evaluated regularly. Adequate anesthesia and a broad-spectrum microbicide should be given prior to the intravitreal injection. Paedriatic Dosage (20kg) No data regarding the Paedriatic dosage details of Ranibizumab is available. Neonatal Dosage (3kg) No data regarding the neonatal dosage details of Ranibizumab is available. High Risk Groups Back to top Warning / Precautions Back to top Storage Conditions Back to top Interference in Pathology Back to top Brands / Trade Names of Ranibizumab Back to top Manufacturers of Ranibizumab in Pakistan Novartis Back to top Previous Drug Generic - Next Drug Generic